SCHEMBL803455

SCHEMBL803455

CC(C)(C)N1CCn2c(c(Cl)c3ccccc32)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.41
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
KDM4E B2RXH2 4/20 0.38
RECQL P46063 1/20 0.38
MAPT P10636 3/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 3/20 0.35
NPC1 O15118 2/20 0.35
LMNA P02545 2/20 0.35
RAB9A P51151 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TLR9 Q9NR96 2/20 0.35
XBP1 P17861 1/20 0.35
PAX8 Q06710 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PBRM1 Q86U86 3/20 0.34
SMARCA4 P51532 4/20 0.33
MITF O75030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14996502 0.80 PDE4A (0.44) PDE4AHTR2AHTR2CKDM4ERECQL
SCHEMBL11956535 0.77 PDE4A (0.41) PDE4AHTR2AHTR2CKDM4EMAPT
SCHEMBL23944789 0.68 PDE4A (0.36) PDE4AKDM4ERECQLMAPTALDH1A1
SCHEMBL19960975 0.67 PABPC1 (0.45) HTR2AHTR2CKDM4ERECQLMAPT
SCHEMBL13698409 0.64 POLB (0.35) MAPTLMNAPOLB
SCHEMBL9844706 0.64 KDM4E (0.60) HTR2AHTR2CKDM4ERECQLMAPT
SCHEMBL16403571 0.62 PDE5A (0.54) KDM4EMAPTALDH1A1NPSR1SMN1; SMN2
SCHEMBL16201628 0.62 PDE4A (0.36) PDE4AKDM4ERECQLMAPTALDH1A1
SCHEMBL24729534 0.60 CHRNA1 (0.30)
SCHEMBL18202213 0.60 PABPC1 (0.49) PDE4AHTR2AHTR2CKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8492559-B2 Substituted indole compounds GRUENENTHAL GMBH (DE) 2013-07-23 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles GRUENENTHAL GMBH (DE) 2011-01-13 US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
US-20100222324-A1 Substituted Indole Compounds GRUENENTHAL GMBH (DE) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN PDE4A 1509/4885HTR2A 1059/4885HTR2C 1903/4885
US-20100222324-A1 Substituted Indole Compounds BDKRB1, BDKRB2, EDNRB PDE4A 2209/4885HTR2A 85/4885HTR2C 221/4885
US-20110009382-A1 Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles BDKRB1, BDKRB2, BRD1 PDE4A 2476/4885HTR2A 713/4885HTR2C 433/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN PDE4A 1509/4885HTR2A 1059/4885HTR2C 1903/4885
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 PDE4A 944/4885HTR2A 475/4885HTR2C 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.